M2 TAMs further enhance immune evasion by upregulating PD-L1 and B7-H4, immune checkpoints induced through direct tumor cell contact and correlated with poor prognosis in glioblastoma and hepatocellular carcinoma (54, 55). This evidence concerns the gene CD274 and glioblastoma.